<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERIVEDGE- vismodegib capsule </strong><br>Genentech, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ERIVEDGE safely and effectively. See full prescribing information for ERIVEDGE. <br><br>ERIVEDGE<span class="Sup">®</span> (vismodegib) capsule for oral use <br>Initial U.S. Approval:  2012</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: EMBRYO-FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta">ERIVEDGE can cause embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> or severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when administered to a pregnant woman. ERIVEDGE is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.  </p>
<p class="Highlighta">Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE therapy. Advise females of reproductive potential to use effective contraception during and after ERIVEDGE therapy. Advise males of the potential risk of ERIVEDGE exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential. Advise pregnant women of the potential risks to a fetus. (<a href="#S5.1">5.1</a>, <a href="#S5.3">5.3</a>, <a href="#S8.1">8.1</a>, <a href="#S8.3">8.3</a>) </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: EMBRYO-FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta">ERIVEDGE can cause embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> or severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when administered to a pregnant woman. ERIVEDGE is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.  </p>
<p class="Highlighta">Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE therapy. Advise females of reproductive potential to use effective contraception during and after ERIVEDGE therapy. Advise males of the potential risk of ERIVEDGE exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential. Advise pregnant women of the potential risks to a fetus. (<a href="#S5.1">5.1</a>, <a href="#S5.3">5.3</a>, <a href="#S8.1">8.1</a>, <a href="#S8.3">8.3</a>) </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">ERIVEDGE<span class="Sup">®</span> (vismodegib) capsule is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended dose is 150 mg orally once daily. (<a href="#S2">2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">150 mg capsules. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Blood donation: Advise patients not to donate blood or blood products while receiving ERIVEDGE and for 7 months after the final dose of ERIVEDGE. (<a href="#S5.2">5.2</a>)</li>
<li>Semen donation: Advise males not to donate semen during and for 3 months after therapy  (<a href="#S5.3">5.3</a>, <a href="#S8.3">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>The most common adverse reactions (incidence of ≥ 10%) are <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">ageusia</span>.</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genentech, Inc. at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Lactation:  Breastfeeding not recommended. (<a href="#S8.2">8.2</a>)</li>
<li>Females and Males of Reproductive Potential: May cause <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> in females. (<a href="#S8.3">8.3</a>)</li>
</ul></div>
<div>
<div></div>
<div><div></div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: EMBRYO-FETAL TOXICITY</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1     Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2     Blood Donation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3     Semen Donation</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1     Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2     Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.3     Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: EMBRYO-FETAL TOXICITY</span></h1>
<p class="First"><span class="Bold">ERIVEDGE can cause embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> or severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when administered to a pregnant woman. ERIVEDGE is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations. </span></p>
<p><span class="Bold">Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE therapy. Advise females of reproductive potential to use effective contraception during and after ERIVEDGE therapy. Advise males of the potential risk of ERIVEDGE exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential. Advise pregnant women of the potential risks to a fetus. [See<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1</a>, <a href="#S5.3">5.3)</a>, <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ERIVEDGE capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of ERIVEDGE is 150 mg taken orally once daily until disease progression or until unacceptable toxicity [see <span class="Italics"><a href="#S14">Clinical Studies (14)</a></span>].</p>
<p>ERIVEDGE may be taken with or without food. Swallow capsules whole. <span class="Bold">Do not open or crush capsules</span>.</p>
<p>If a dose of ERIVEDGE is missed, do not make up that dose; resume dosing with the next scheduled dose.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ERIVEDGE (vismodegib) capsules, 150 mg. The capsule has a pink opaque body and a grey opaque cap, with "150 mg" printed on the capsule body and "VISMO" printed on the capsule cap in black ink.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1     Embryo-Fetal Toxicity</h2>
<p class="First">Based on its mechanism of action, ERIVEDGE can cause embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> or severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> when administered to a pregnant woman. In animal reproduction studies, vismodegib was embryotoxic, fetotoxic, and teratogenic at maternal exposures lower than the human exposures at the recommended dose of 150 mg/day.</p>
<p>Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE therapy. Advise females of reproductive potential to use effective contraception during therapy with ERIVEDGE and for 7 months after the final dose. Advise male patients to use condoms, even after a vasectomy, to avoid potential drug exposure in pregnant partners and female partners of reproductive potential during therapy and for 3 months after the final dose of ERIVEDGE. Advise pregnant women of the potential risk to a fetus [see<span class="Italics"><a href="#S8.1"> Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3) </a></span><span class="Italics">and <a href="#S12.1">Clinical Pharmacology (12.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2     Blood Donation</h2>
<p class="First">Advise patients not to donate blood or blood products while receiving ERIVEDGE and for 7 months after the final dose of ERIVEDGE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3     Semen Donation</h2>
<p class="First">Vismodegib is present in semen. It is not known if the amount of vismodegib in semen can cause embryo-fetal harm. Advise male patients not to donate semen during and for 3 months after the final dose of ERIVEDGE [see<span class="Italics"><a href="#S8.1"> Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a></span>]<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1     Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>ERIVEDGE capsule was administered as monotherapy at doses ≥ 150 mg orally daily in four open-label, uncontrolled, dose-ranging or fixed single dose clinical trials enrolling a total of 138 patients with advanced basal cell carcinoma (BCC). The median age of these patients was 61 years (range 21 to 101), 100% were White (including Hispanics), and 64% were male. The median duration of treatment was approximately 10 months (305 days; range 0.7 to 36 months); 111 patients received ERIVEDGE for 6 months or longer.</p>
<p>The most common adverse reactions (≥ 10%) were <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">ageusia</span> (<a href="#t1">Table 1</a>).</p>
<a name="t1"></a><table width="80%">
<caption><span>Table 1:    Adverse Reactions Occurring in ≥ 10% of Advanced BCC Patients</span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">MedDRA Preferred Term<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="3">All aBCC<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> Patients (N = 138)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">All Grades<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a> (%)</th>
<th class="Rrule" align="center">Grade 3 (%)</th>
<th class="Rrule" align="center">Grade 4 (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>MedDRA = Medical Dictionary for Regulatory Activities.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>aBCC = Advanced Basal Cell Carcinoma.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Grading according to NCI-CTCAE v3.0.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">42 (30.4%)</td>
<td class="Rrule" align="center">1 (0.7%)</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">40 (29.0%)</td>
<td class="Rrule" align="center">1 (0.7%)</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">29 (21.0%)</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">19 (13.8%)</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">General disorders and administration site conditions</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">55 (39.9%)</td>
<td class="Rrule" align="center">7 (5.1%)</td>
<td class="Rrule" align="center">1 (0.7%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Investigations</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></td>
<td class="Rrule" align="center">62 (44.9%)</td>
<td class="Rrule" align="center">10 (7.2%)</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Metabolism and nutrition disorders</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center">35 (25.4%)</td>
<td class="Rrule" align="center">3 (2.2%)</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">99 (71.7%)</td>
<td class="Rrule" align="center">5 (3.6%)</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span></td>
<td class="Rrule" align="center">22 (15.9%)</td>
<td class="Rrule" align="center">1 (0.7%)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">76 (55.1%)</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Ageusia</span></td>
<td class="Rrule" align="center">15 (10.9%)</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Skin and subcutaneous tissue disorders</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">88 (63.8%)</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>: </span></p>
<p>In clinical trials, a total of 3 of 10 pre-menopausal women developed <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> while receiving ERIVEDGE [see <span class="Italics"><a href="#S13.1">Non-Clinical Toxicology (13.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Laboratory Abnormalities:</span></p>
<p>Treatment-emergent Grade 3 laboratory abnormalities observed in clinical trials were <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in 6 patients (4%), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in 2 patients (1%), and <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> in 3 patients (2%).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Clinically relevant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> are not expected between vismodegib and a substrate, inducer or inhibitor of cytochrome 450 enzymes or an inhibitor of P-glycoprotein (P-gp) or between vismodegib and gastric pH elevating agents [see<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>Based on its mechanism of action and animal reproduction studies, ERIVEDGE can cause fetal harm when administered to a pregnant woman [see<span class="Italics"><a href="#S12.1"> Clinical Pharmacology (12.1)</a></span>]. In animal reproduction studies, oral administration of vismodegib during organogenesis at doses below the recommended human dose resulted in embryotoxicity, fetotoxicity, and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats [see<span class="Italics"><a href="#data"> Data</a></span>]. There are no human data on the use of ERIVEDGE in pregnant women. Advise pregnant women of the potential risk to a fetus. Report pregnancies to Genentech at 1-888-835-2555.</p>
<p>The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated population is unknown. In the U.S. general population, the estimated background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="data"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2.1"></a><p></p>
<p class="First"><span class="Underline">Animal Data</span></p>
<p>In an embryo-fetal developmental toxicity study, pregnant rats were administered vismodegib orally at doses of 10, 60, or 300 mg/kg/day during the period of organogenesis. Pre- and post-implantation loss were increased at doses of ≥ 60 mg/kg/day (approximately ≥ 2 times the systemic exposure (AUC) in patients at the recommended human dose), which included early resorption of 100% of the fetuses. A dose of 10 mg/kg/day (approximately 0.2 times the AUC in patients at the recommended dose) resulted in malformations (including missing and/or fused digits, open perineum and craniofacial anomalies) and retardations or variations (including dilated renal pelvis, dilated ureter, and incompletely or unossified sternal elements, centra of vertebrae, or proximal phalanges and claws).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="77290-5">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2     Lactation</h2>
<p class="First">No data are available regarding the presence of vismodegib in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Because of the potential for serious adverse reactions in breastfed infants from ERIVEDGE, advise a nursing woman that breastfeeding is not recommended during therapy with ERIVEDGE and for 7 months after the final dose.</p>
</div>
<div class="Section" data-sectionCode="77291-3">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3     Females and Males of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Testing</span></p>
<p>Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Italics">Contraception</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2.1"></a><p></p>
<p class="First"><span class="Underline">Females</span></p>
<p>Based on its mechanism of action and animal data, ERIVEDGE can cause fetal harm when administered to a pregnant woman [see<span class="Italics"><a href="#S8.1"> Use in Specific Populations (8.1)</a></span>]. Advise females of reproductive potential to use effective contraception during therapy and for 7 months after the final dose of ERIVEDGE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2.2"></a><p></p>
<p class="First"><span class="Underline">Males</span></p>
<p>Vismodegib is present in semen [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. It is not known if the amount of vismodegib in semen can cause embryo-fetal harm. Advise male patients to use condoms, even after a vasectomy, to avoid drug exposure to pregnant partners and female partners of reproductive potential during therapy with and for 3 months after the final dose of ERIVEDGE. Advise males of the potential risk to an embryo or fetus if a female partner of reproductive potential is exposed to ERIVEDGE. Advise males not to donate semen during therapy with and for 3 months after the final dose of ERIVEDGE.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3.1"></a><p></p>
<p class="First"><span class="Underline">Females</span></p>
<p><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> can occur in females of reproductive potential. Reversibility of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> is unknown [see<span class="Italics"><a href="#S6"> Adverse Reactions (6)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of ERIVEDGE capsule have not been established in pediatric patients.</p>
<p>In repeat-dose toxicology studies in rats, administration of oral vismodegib resulted in toxicities in bone and teeth. Effects on bone consisted of closure of the epiphyseal growth plate when oral vismodegib was administered for 26 weeks at ≥ 50 mg/kg/day (approximately ≥ 0.4 times the systemic exposure (AUC) in patients at the recommended human dose). Abnormalities in growing incisor teeth (including degeneration/<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of odontoblasts, formation of fluid-filled <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> in the dental pulp, ossification of the root canal, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> resulting in breakage or loss of teeth) were observed after administration of oral vismodegib at ≥ 15 mg/kg/day (approximately ≥ 0.2 times the AUC in patients at the recommended human dose).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of ERIVEDGE capsule did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment is required in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no information on overdosage in humans. In clinical trials, ERIVEDGE capsule was administered at 540 mg orally once daily; exposure did not increase between 150 mg and 540 mg daily.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Vismodegib is an inhibitor of the hedgehog (Hh) signaling pathway, which is described chemically as 2-Chloro-<span class="Italics">N</span>-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide. The molecular formula is C<span class="Sub">19</span>H<span class="Sub">14</span>Cl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S. The molecular weight is 421.30 g/mol and the structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a&amp;name=erivedge-01.jpg"></div>
<p>Vismodegib is a crystalline free base with a pKa (pyridinium cation) of 3.8, appearing as a white to tan powder. The solubility of vismodegib is pH dependent with 0.1 μg/mL at pH 7 and 0.99 mg/mL at pH 1. The partition coefficient (log P) is 2.7.</p>
<p>Each ERIVEDGE (vismodegib) capsule for oral administration contains 150 mg vismodegib and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, sodium lauryl sulfate, povidone, sodium starch glycolate, talc, and magnesium stearate (non-bovine). The capsule shell contains gelatin, titanium dioxide, red iron oxide, and black iron oxide. The black printing ink contains shellac and black iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Cardiac Electrophysiology</span></p>
<p>The QTc interval was not affected by therapeutic doses of ERIVEDGE in a thorough QTc trial.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>The single dose absolute bioavailability of vismodegib is 31.8%. Absorption is saturable as evidenced by the lack of dose proportional increase in exposure after a single dose of 270 mg or 540 mg vismodegib. ERIVEDGE capsule may be taken without regard to meals because the systemic exposure of vismodegib at steady state is not affected by food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>The volume of distribution of vismodegib ranges from 16.4 to 26.6 L. Vismodegib plasma protein binding in patients is greater than 99%. Vismodegib binds to both human serum albumin and alpha-1-acid glycoprotein (AAG) and binding to AAG is saturable.</p>
<p>In a pharmacokinetic study, male patients (n=3) had an average concentration of vismodegib in semen on day 8 that was 6.5% of the average steady state concentration (C<span class="Sub">ss</span>) observed in plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Greater than 98% of the total circulating drug-related components are the parent drug. Metabolic pathways of vismodegib in humans include oxidation, glucuronidation, and pyridine ring cleavage. The two most abundant oxidative metabolites recovered in feces are produced <span class="Italics">in vitro</span> by recombinant CYP2C9 and CYP3A4/5.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Elimination</span></p>
<p>Vismodegib and its metabolites are eliminated primarily by the hepatic route with 82% of the administered dose recovered in the feces and 4.4% recovered in urine. The estimated elimination half-life (t<span class="Sub">1/2</span>) of vismodegib is 4 days after continuous once-daily dosing and 12 days after a single dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> In a dedicated clinical study, the mean systemic exposure (AUC <span class="Sub">0-24hr</span>) of vismodegib was increased by 24% in patients with mild (n=8), 31% in patients with moderate (n=6) and decreased 14% in patients with severe (n=3) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when compared to patients with normal hepatic function (n=9) after 8 days of daily ERIVEDGE administration. The NCI Organ Dysfunction Working Group criteria for <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were used in the study. Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was defined as normal total bilirubin and aspartate transaminase (AST) &gt; upper limit of normal (ULN) or total bilirubin &gt; 1.0 to 1.5 times ULN, moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> as total bilirubin &gt; 1.5 to 3.0 times ULN, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> as total bilirubin &gt; 3.0 to 10.0 times ULN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Renal excretion of vismodegib after oral administration of ERIVEDGE is low (&lt;5%). The population pharmacokinetic analysis suggested no clinically relevant effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the systemic exposure of vismodegib, based on pharmacokinetic data from patients with mild (CLcr 50 to 79 mL/min, n=58), and moderate (CLcr 30 to 49 mL/min, n=16) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Weight, Age, and Sex:</span> The results of a population pharmacokinetic analysis suggested no clinically relevant effect of weight (range: 41-140 kg), age (range: 26-89 years), and sex on the systemic exposure of vismodegib.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Italics">Drug Interaction Studies</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Effect of Drugs on Vismodegib: </span>Coadministration of ERIVEDGE with fluconazole (a moderate CYP2C9 inhibitor and moderate CYP3A4 inhibitor) increased mean AUC<span class="Sub">0-24hr</span> and steady-state concentrations of vismodegib by 1.3-fold in healthy subjects. A strong inhibitor of CYP3A4 and P-gp (itraconazole) or a proton pump inhibitor (rabeprazole) had no effect on the steady-state systemic exposure of vismodegib when coadministered with ERIVEDGE in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics">Effects of Vismodegib on Other Drugs:</span> Results of a drug interaction study conducted in cancer patients demonstrated that the systemic exposure of rosiglitazone (a CYP2C8 substrate) or oral contraceptives (ethinyl estradiol and norethindrone) is not altered when either drug is coadministered with vismodegib.</p>
<p>In vitro studies suggest that vismodegib is an inhibitor of CYP2C8, CYP2C9, CYP2C19 and the transporter BCRP and that vismodegib is not an inducer of CYP1A2, CYP2B6, or CYP3A.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies with vismodegib have not been conducted. Pilomatricoma (a benign cutaneous neoplasm) was observed in rats administered oral vismodegib for 26 weeks at 100 mg/kg/day (approximately 0.8 times the systemic exposure (AUC) in patients at the recommended human dose).</p>
<p>Vismodegib was not mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay and was not clastogenic in the <span class="Italics">in vitro </span>human chromosomal aberration assay in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or in the <span class="Italics">in vivo</span> rat bone marrow micronucleus assay.</p>
<p>Studies to assess the potential of vismodegib to affect fertility have not been conducted; however, data from repeat-dose toxicology studies in rats and dogs indicate that male and female reproductive function and fertility may be impaired in patients receiving ERIVEDGE capsule. In a 26-week toxicology study in rats, a relative decrease in percent motile sperm was observed at ≥ 15 mg/kg/day (approximately ≥ 0.3 times the AUC in patients at the recommended human dose). In dogs, increased numbers of degenerating germ cells and hypospermia were observed in young animals administered oral vismodegib for 4 weeks at ≥ 50 mg/kg/day (approximately ≥ 2 times the AUC in patients at the recommended human dose). No corresponding findings were observed in sexually mature dogs at similar doses in 13-week and 26-week toxicology studies. A decrease in the number of corpora lutea was observed in female rats administered oral vismodegib for 26 weeks at 100 mg/kg/day (approximately 0.8 times the AUC in patients at the recommended human dose).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<p class="First">Neurologic effects characterized as limb or body <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span> were observed in rats administered oral vismodegib for 4 weeks or longer at ≥ 50 mg/kg/day (approximately ≥ 0.4 times the AUC in patients at the recommended human dose). These observations resolved upon discontinuation of dosing and were not associated with microscopic findings.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">A single, international, single-arm, multi-center, open-label, 2-cohort trial was conducted in 104 patients with either metastatic basal cell carcinoma (mBCC) (n = 33) or locally advanced BCC (laBCC) (n = 71). Patients with laBCC were required to have lesions that had recurred after radiotherapy, unless radiotherapy was contraindicated or inappropriate (e.g. Gorlin syndrome; limitations because of location of tumor or cumulative prior radiotherapy dose), and where the lesions were either unresectable or surgical resection would result in substantial <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>. Patients were to receive 150 mg vismodegib per day orally until disease progression or unacceptable toxicity.</p>
<p>The major efficacy outcome measure of the trial was objective response rate (ORR) as assessed by an independent review facility (IRF). In the mBCC cohort, tumor response was assessed according to the Response Evaluation Criteria in <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span> (RECIST) version 1.0. In the laBCC cohort, tumor response evaluation included measurement of externally assessable tumor (including <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span>) and assessment for ulceration in photographs, radiographic assessment of target lesions (if appropriate), and tumor biopsy. An objective response in laBCC required at least one of the following criteria <span class="Underline">and</span> absence of any criterion for disease progression: (1) ≥ 30% reduction in lesion size [sum of the longest diameter (SLD)] from baseline in target lesions by radiographic assessment; (2) ≥ 30% reduction in SLD from baseline in externally visible dimension of target lesions; (3) complete resolution of ulceration in all target lesions. Complete response was defined as objective response (as defined above) with no residual BCC on sampling tumor biopsy. Disease progression was defined as any of the following: (1) ≥ 20% increase in the SLD from nadir in target lesions (either by radiography or by externally visible dimension); (2) new ulceration of target lesions persisting without evidence of healing for at least 2 weeks; (3) new lesions by radiographic assessment or physical examination; (4) progression of non-target lesions by RECIST.</p>
<p>Of the 104 patients enrolled, 96 patients were evaluable for ORR. Twenty-one percent of patients carried a diagnosis of Gorlin syndrome. The median age of the efficacy evaluable population was 62 years (46% were at least 65 years old), 61% male and 100% White. For the mBCC cohort (n = 33), 97% of patients had prior therapy including surgery (97%), radiotherapy (58%), and systemic therapies (30%). For the laBCC cohort (n = 63), 94% of patients had prior therapies including surgery (89%), radiotherapy (27%), and systemic/topical therapies (11%). The median duration of treatment was 10.2 months (range 0.7 to 18.7 months).</p>
<p>The key outcome measures are presented in <a href="#t2">Table 2</a>, below.</p>
<a name="t2"></a><table width="75%">
<caption><span>Table 2:    Objective Response Rate: Efficacy-Evaluable Patients<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="center">mBCC<br>(n = 33)</th>
<th class="Rrule" align="center">laBCC<br>(n = 63)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Patients who received at least one dose of ERIVEDGE with independent pathologist-confirmed diagnosis of BCC</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>IRF = Independent Review Facility</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>For laBCC, complete response was defined as objective response with no residual BCC on sampling tumor biopsy.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>CI = Confidence Interval</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">¶</a></dt>
<dd>NE = Not estimable</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">IRF<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>-Confirmed ORR, n (%)</span></td>
<td align="center">10 (30.3)</td>
<td class="Rrule" align="center">27 (42.9)</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="Bold">(95% CI)</span>
</td>
<td align="center">(15.6, 48.2)</td>
<td class="Rrule" align="center">(30.5, 56.0)</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="Bold">Complete response<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a></span>
</td>
<td align="center">0 (0.0)</td>
<td class="Rrule" align="center">13 (20.6)</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="Bold">Partial response </span>
</td>
<td align="center">10 (30.3)</td>
<td class="Rrule" align="center">14 (22.2)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Median Response Duration (months) </span></td>
<td align="center">7.6</td>
<td class="Rrule" align="center">7.6</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="Bold">(95% CI<a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a>)</span>
</td>
<td align="center">(5.6, NE<a name="footnote-reference-8" href="#footnote-8" class="Sup">¶</a>)</td>
<td class="Rrule" align="center">(5.7, 9.7)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each ERIVEDGE (vismodegib) capsule has a pink opaque body and a grey opaque cap with "150 mg" printed on the capsule body and "VISMO" printed on the capsule cap in black ink. ERIVEDGE capsules are available in bottles of 28 capsules (NDC 50242-140-01).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See <span class="Italics"><a href="#MED">FDA-approved patient labeling (Medication Guide)</a>.</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Italics">Administration Instructions</span></p>
<ul><li>Advise patients to swallow ERIVEDGE capsules whole and not to crush or open the capsules.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Italics">Embryo-Fetal Toxicity</span></p>
<ul>
<li>Advise pregnant women of the potential risk to a fetus [see<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a></span>].</li>
<li>Advise females of reproductive potential to use effective contraception during therapy with and for 7 months after the final dose of ERIVEDGE [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a></span>].</li>
<li>Advise males, even those with prior vasectomy, to use condoms to avoid potential drug exposure in both pregnant partners and female partners of reproductive potential during therapy with and for 3 months after the final dose of ERIVEDGE [see<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a> and <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a></span>].</li>
<li>Advise female patients and female partners of male patients to contact their healthcare provider with a known or suspected pregnancy. Report pregnancies to Genentech at 1-888-835-2555 [see<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a> and <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Italics">Semen Donation</span></p>
<ul><li>Advise males not to donate semen during therapy with and for 3 months after the final dose of ERIVEDGE.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<p class="First"><span class="Italics">Lactation</span></p>
<ul><li>Advise women that breastfeeding is not recommended during therapy with ERIVEDGE and for 7 months after the final dose [see<span class="Italics"><a href="#S8.2"> Use in Specific Populations (8.2)</a></span>].</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<p class="First"><span class="Italics">Blood Donation</span></p>
<ul><li>Advise patients not to donate blood or blood products while taking ERIVEDGE and for 7 months after the final dose of ERIVEDGE.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">ERIVEDGE<span class="Sup">®</span> [vismodegib] capsule</p>
<p>Manufactured by:<br>Patheon, Inc.<br>Mississauga, Canada</p>
<p>ERIVEDGE is a registered trademark of Genentech, Inc.<br><span class="Sup">©</span>2015 Genentech, Inc.</p>
<p>Distributed by:<br><span class="Bold">Genentech USA, Inc</span>.<br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MED"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">ERIVEDGE</span><span class="Sup">®</span><span class="Bold"> (EH-rih-vej)</span><br>(vismodegib)<br>capsule</p>
<p><a name="mi"></a><span class="Bold">What is the most important information I should know about ERIVEDGE?</span></p>
<p><span class="Bold">ERIVEDGE can cause your baby to die before it is born (be stillborn) or cause your baby to have severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </span></p>
<p><span class="Bold">For females who can become pregnant:</span></p>
<ul>
<li>You should talk with your healthcare provider about the risks of ERIVEDGE to your unborn child.</li>
<li>Your healthcare provider will do a pregnancy test before you start taking ERIVEDGE.</li>
<li>In order to avoid pregnancy, you should use birth control during treatment and for 7 months after your final dose of ERIVEDGE. Talk with your healthcare provider about what birth control method is right for you during this time.</li>
<li>Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed. </li>
<li>Tell your healthcare provider right away if you become pregnant or think that you may be pregnant.</li>
</ul>
<p><span class="Bold">For males:</span></p>
<ul>
<li>ERIVEDGE is present in semen. Do not donate semen while you are taking ERIVEDGE and for 3 months after your final dose. </li>
<li>You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with ERIVEDGE and for 3 months after your final dose to protect your female partner from being exposed to ERIVEDGE. </li>
<li>Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking ERIVEDGE.</li>
</ul>
<p><span class="Bold">Exposure to ERIVEDGE during pregnancy:</span></p>
<p>If you think that you or your female partner may have been exposed to ERIVEDGE during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with ERIVEDGE, you or your healthcare provider should report your pregnancy to Genentech at 1-888-835-2555.</p>
<p><span class="Bold">What is ERIVEDGE?</span></p>
<p>ERIVEDGE is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body, or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation.</p>
<p>It is not known if ERIVEDGE is safe and effective in children. </p>
<p><span class="Bold">What should I tell my healthcare provider before taking ERIVEDGE?</span></p>
<p><span class="Bold">Before taking ERIVEDGE, tell your healthcare provider if you:</span></p>
<ul>
<li>
<span class="Bold">are pregnant or plan to become pregnant.</span> See <span class="Bold">"<a href="#mi">What is the most important information I should know about ERIVEDGE?</a>"</span>
</li>
<li>
<span class="Bold">are breastfeeding or plan to breastfeed.</span> It is not known if ERIVEDGE passes into your breast milk. You should not breastfeed during treatment and for 7 months after your final dose of ERIVEDGE. Talk to your healthcare provider about the best way to feed your baby during this time.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How should I take ERIVEDGE?</span></p>
<ul>
<li>Take ERIVEDGE exactly as your healthcare provider tells you. </li>
<li>You can take ERIVEDGE with or without food.</li>
<li>Swallow ERIVEDGE capsules whole. <span class="Bold">Do not open or crush the capsules. </span>
</li>
<li>Take ERIVEDGE one time each day.</li>
<li>If you miss a dose, skip the missed dose. Just take your next scheduled dose.</li>
</ul>
<p><span class="Bold">What should I avoid while taking ERIVEDGE?</span></p>
<ul>
<li>Do not donate blood or blood products while you are taking ERIVEDGE and for 7 months after your final dose. </li>
<li>Do not donate semen while you are taking ERIVEDGE and for 3 months after your final dose.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ERIVEDGE?</span></p>
<p><span class="Bold">ERIVEDGE can cause serious side effects, including:</span></p>
<ul><li>See <span class="Bold">"<a href="#mi">What is the most important information I should know about ERIVEDGE?</a>"</span>
</li></ul>
<p>The most common side effects of ERIVEDGE are:</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></li>
<li>change in how things taste or <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span></li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
</ul></td>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> </li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
</ul></td>
</tr></tbody>
</table>
<p>ERIVEDGE can cause absence of menstrual periods (<span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>) in females who are able to become pregnant. It is not known if <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> is permanent. Talk to your healthcare provider if you have concerns about fertility.</p>
<p>These are not all the possible side effects of ERIVEDGE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p>You may also report side effects to Genentech, Inc. at 1-888-835-2555.</p>
<p><span class="Bold">How should I store ERIVEDGE?</span></p>
<ul><li>Store ERIVEDGE at room temperature between 68°F to 77°F (20°C to 25°C).</li></ul>
<p><span class="Bold">Keep ERIVEDGE and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of ERIVEDGE</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ERIVEDGE for a condition for which it was not prescribed. Do not give ERIVEDGE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ERIVEDGE that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in ERIVEDGE?</span></p>
<p>Active ingredient: vismodegib</p>
<p>Inactive ingredients: microcrystalline cellulose, lactose monohydrate, sodium lauryl sulfate, povidone, sodium starch glycolate, talc, magnesium stearate (non-bovine). The capsule shell contains gelatin, titanium dioxide, red iron oxide, and black iron oxide. The black printing ink contains shellac and black iron oxide.</p>
<p>Manufactured by: Patheon, Inc. Mississauga, Canada<br>Distributed by: <span class="Bold">Genentech USA, Inc.</span> A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990<br>For more information, call 1-855-737-4833 or go to www.erivedge.com<br>ERIVEDGE is a registered trademark of Genentech, Inc.<br>©2015 Genentech, Inc.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br>Revised:  05/2015</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Representative sample of labeling (see the <a href="#S16">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Label</h1>
<p class="First">NDC 50242-140-01</p>
<p><span class="Bold">Erivedge<span class="Sup">®</span></span><br>(vismodegib)<br>capsules</p>
<p><span class="Bold">150 mg</span></p>
<p>Each capsule contains 150 mg of<br>vismodegib</p>
<p><span class="Bold">Attention Pharmacist: Dispense the<br> accompanying Medication Guide to <br>each patient.</span></p>
<p><span class="Bold">Rx only</span></p>
<p>28 capsules<br><span class="Bold">Genentech</span></p>
<p>10161754</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a&amp;name=erivedge-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERIVEDGE 		
					</strong><br><span class="contentTableReg">vismodegib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-140</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>vismodegib</strong> (vismodegib) </td>
<td class="formItem">vismodegib</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GRAY (gray opaque) , PINK (pink opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (hard capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VISMO;150;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-140-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">28  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203388</td>
<td class="formItem">01/30/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">F. Hoffmann-La Roche Ltd</td>
<td class="formItem"></td>
<td class="formItem">482242971</td>
<td class="formItem">ANALYSIS(50242-140)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">F. Hoffmann-La Roche Ltd</td>
<td class="formItem"></td>
<td class="formItem">485244961</td>
<td class="formItem">ANALYSIS(50242-140), PACK(50242-140), LABEL(50242-140)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Roche Pharma AG</td>
<td class="formItem"></td>
<td class="formItem">315009878</td>
<td class="formItem">ANALYSIS(50242-140)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2691dd1f-c172-48e0-a55e-0a4b14ec1b9d</div>
<div>Set id: eb368bb6-80e3-4df9-8a85-91df0a2ada6a</div>
<div>Version: 4</div>
<div>Effective Time: 20150530</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
